Compare DexCom, Inc. (DXCM) vs Macerich Company (The) Common Stock (MAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Macerich Company (The) Common Stock — how do they compare? DexCom, Inc. trades at $84.41 (market cap $32.09B), while Macerich Company (The) Common Stock trades at $22.18 (market cap $6.39B). The key difference: DexCom, Inc. is far larger — about 5× Macerich Company (The) Common Stock's market cap, and Macerich Company (The) Common Stock pays a 3.02% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Macerich Company (The) Common Stock for 0 Days on average.
| DXCM | MAC | |
|---|---|---|
Market Cap | $32.09B | $6.39B |
Volume | 3,819,730 | 2,684,151 |
Sector | Health | Real Estate |
52-Week High | $92.34 | $26.51 |
52-Week Low | $54.84 | $16.20 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $31.54B | $11.07B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $83.47, down 2.85% on the day, amid a generally bullish technical and fundamental backdrop. The stock shows strong revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million, and has consistently beaten earnings expectations. Analyst consensus is strongly positive with a price target of $96.14, and recent news highlights expansion opportunities in the Type 2 diabetes CGM market.
The outlook for DXCM is positive, driven by solid financial performance and market expansion potential. Key opportunities include growing adoption of its CGM systems, while risks involve competitive pressures and reimbursement challenges. The stock presents a compelling case for growth-oriented investors, supported by strong analyst backing and institutional interest.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Macerich Company (The) Common Stock
The Macerich Company is a real estate investment trust that owns, operates, and redevelops shopping centers concentrated in California, the Pacific Northwest, and other major US markets.
Read more on MAC →
